Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Using a laboratory test (VeriStrat), patients with relapsed squamous cell lung cancer are
assigned to two strata, VSG (VeriStrat Good) and VSP (VeriStrat Poor). They are then
randomized between an EGFR-TK inhibitor (erlotinib) and chemotherapy (Docetaxel).
It is hypothesized that the VeriStrat test results are able to predict the benefit of
treatment with erlotinib vs docetaxel. This would suggest a significant improvement in
progression-free survival for VSG patients when treated with Erlotinib, and no significant
improvement in VSP patients who receive the same treatment.